A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series and booster doses administered in the U.S. would be bivalent. The committee also is expected to discuss simplifying future COVID-19 vaccine use to authorize or approve a two-dose series for certain young children, older adults and people with compromised immunity and only one dose for all other individuals; as well as periodic updates to COVID-19 vaccines, including for use this fall. 

Related News Articles

Headline
The House last night voted 220-210 to pass legislation (H.R.382) that would immediately terminate the COVID-19 public health emergency, and 227-203 to pass…
Headline
The AHA is offering a new set of social messages and assets for February to encourage the public to get vaccinated and boosted against COVID-19. The new…
Headline
A Food and Drug Administration advisory committee unanimously voted today to recommend harmonizing the composition of all COVID-19 vaccine primary series and…
Headline
In a study released today by the Centers for Disease Control and Prevention, a single bivalent COVID-19 vaccine booster provided additional protection against…
Headline
Evusheld may not prevent COVID-19 in immunocompromised individuals exposed to the XBB.1.5 omicron subvariant, because the treatment has failed to neutralize…
Headline
In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported…